Stock analysts at Roth Capital assumed coverage on shares of Sanuwave Health (NASDAQ:SNWV - Get Free Report) in a report released on Tuesday, MarketBeat.com reports. The firm set a "buy" rating and a $49.00 price target on the stock. Roth Capital's price objective suggests a potential upside of 35.21% from the company's previous close. Roth Capital also issued estimates for Sanuwave Health's Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.27 EPS, FY2025 earnings at ($0.36) EPS, Q1 2026 earnings at $0.07 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.36 EPS, FY2026 earnings at $0.84 EPS and FY2027 earnings at $1.72 EPS.
Separately, Wall Street Zen downgraded Sanuwave Health from a "buy" rating to a "hold" rating in a research note on Saturday, May 24th.
Check Out Our Latest Stock Analysis on Sanuwave Health
Sanuwave Health Price Performance
Shares of SNWV traded down $2.23 during trading hours on Tuesday, hitting $36.24. The company had a trading volume of 49,625 shares, compared to its average volume of 52,421. The company has a market cap of $310.58 million, a P/E ratio of -7.95 and a beta of 1.24. Sanuwave Health has a one year low of $5.21 and a one year high of $39.83. The business's fifty day moving average price is $32.33.
Sanuwave Health (NASDAQ:SNWV - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.66) earnings per share for the quarter. The firm had revenue of $9.34 million during the quarter.
Insider Buying and Selling
In other Sanuwave Health news, COO Peter Stegagno sold 1,862 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $27.71, for a total transaction of $51,596.02. Following the completion of the transaction, the chief operating officer owned 2,032 shares of the company's stock, valued at $56,306.72. This represents a 47.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Iulian Cioanta sold 3,639 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $31.60, for a total value of $114,992.40. Following the completion of the sale, the insider directly owned 41 shares of the company's stock, valued at approximately $1,295.60. This represents a 98.89% decrease in their position. The disclosure for this sale can be found here. 14.90% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Sanuwave Health
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. purchased a new position in Sanuwave Health in the first quarter valued at $337,000. Evernest Financial Advisors LLC purchased a new stake in shares of Sanuwave Health during the 2nd quarter worth approximately $823,000. AWM Investment Company Inc. purchased a new stake in Sanuwave Health in the 1st quarter valued at approximately $18,153,000. Solas Capital Management LLC purchased a new position in shares of Sanuwave Health during the 1st quarter worth $20,658,000. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in shares of Sanuwave Health during the 1st quarter worth $47,000. Institutional investors and hedge funds own 42.53% of the company's stock.
About Sanuwave Health
(
Get Free Report)
SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.
Read More
Before you consider Sanuwave Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanuwave Health wasn't on the list.
While Sanuwave Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
